Cargando…
Reputation and Power : Organizational Image and Pharmaceutical Regulation at the FDA /
The U.S. Food and Drug Administration is the most powerful regulatory agency in the world. How did the FDA become so influential? And how exactly does it wield its extraordinary power? Reputation and Power traces the history of FDA regulation of pharmaceuticals, revealing how the agency's organ...
| Autor principal: | |
|---|---|
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Princeton :
Princeton University Press,
2010.
|
| Colección: | Book collections on Project MUSE.
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a22000004a 4500 | ||
|---|---|---|---|
| 001 | musev2_31134 | ||
| 003 | MdBmJHUP | ||
| 005 | 20230905043305.0 | ||
| 006 | m o d | ||
| 007 | cr||||||||nn|n | ||
| 008 | 100812s2010 nju o 00 0 eng d | ||
| 020 | |a 9781400835119 | ||
| 020 | |z 9780691141800 | ||
| 020 | |z 9780691141794 | ||
| 035 | |a (OCoLC)655342133 | ||
| 040 | |a MdBmJHUP |c MdBmJHUP | ||
| 100 | 1 | |a Carpenter, Daniel P., |d 1967- |e author. | |
| 245 | 1 | 0 | |a Reputation and Power : |b Organizational Image and Pharmaceutical Regulation at the FDA / |c Daniel Carpenter. |
| 264 | 1 | |a Princeton : |b Princeton University Press, |c 2010. | |
| 264 | 3 | |a Baltimore, Md. : |b Project MUSE, |c 2015 | |
| 264 | 4 | |c ©2010. | |
| 300 | |a 1 online resource (824 pages): |b illustrations, map | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 0 | |a Princeton studies in American politics : historical, international, and comparative perspectives | |
| 505 | 0 | 0 | |g Introduction: |t The gatekeeper -- |t Reputation and regulatory power -- |t Reputation and gatekeeping authority : the federal Food, Drug, and Cosmetic Act of 1938 and its aftermath -- |t The ambiguous emergence of American pharmaceutical regulation, 1944-1961 -- |t Reputation and power crystallized : thalidomide, Frances Kelsey, and phased experiment, 1961-1966 -- |t Reputation and power institutionalized : scientific networks, congressional hearings, and judicial affirmations, 1963-1986 -- |t Reputation and power contested : emboldened audiences in cancer and AIDS, 1977-1992 -- |t Reputation and the organizational politics of new drug review -- |t The governance of research and development : gatekeeping power, conceptual guidance, and regulation by satellite -- |t The other side of the gate : reputation, power, and post-market regulation -- |t The detente of firm and regulator -- |t American pharmaceutical regulations in international context : audiences, comparisons, and dependencies -- |g Conclusion: |t A reputation in brief. |
| 520 | |a The U.S. Food and Drug Administration is the most powerful regulatory agency in the world. How did the FDA become so influential? And how exactly does it wield its extraordinary power? Reputation and Power traces the history of FDA regulation of pharmaceuticals, revealing how the agency's organizational reputation has been the primary source of its power, yet also one of its ultimate constraints. Daniel Carpenter describes how the FDA cultivated a reputation for competence and vigilance throughout the last century, and how this organizational image has enabled the agency to regulate an industr. | ||
| 546 | |a English. | ||
| 588 | |a Description based on print version record. | ||
| 610 | 1 | 7 | |a United States. |b Food and Drug Administration. |2 fast |0 (OCoLC)fst00549734 |
| 610 | 1 | 2 | |a United States |b Food and Drug Administration |
| 610 | 1 | 0 | |a United States. |b Food and Drug Administration. |
| 650 | 7 | |a Pharmaceutical policy. |2 fast |0 (OCoLC)fst01060194 | |
| 650 | 7 | |a Drugs |x Research. |2 fast |0 (OCoLC)fst00898894 | |
| 650 | 7 | |a MEDICAL |x Pharmacology. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Allied Health Services |x General. |2 bisacsh | |
| 650 | 6 | |a Medicaments |x Recherche |z États-Unis. | |
| 650 | 6 | |a Medicaments |x Politique gouvernementale |z États-Unis. | |
| 650 | 0 | |a Drugs |x Research |z United States. | |
| 650 | 0 | |a Pharmaceutical policy |z United States. | |
| 651 | 7 | |a United States. |2 fast |0 (OCoLC)fst01204155 | |
| 655 | 7 | |a Electronic books. |2 local | |
| 710 | 2 | |a Project Muse. |e distributor | |
| 830 | 0 | |a Book collections on Project MUSE. | |
| 856 | 4 | 0 | |z Texto completo |u https://projectmuse.uam.elogim.com/book/31134/ |
| 945 | |a Project MUSE - Custom Collection | ||
| 945 | |a Project MUSE - Archive Complete Supplement III | ||
| 945 | |a Project MUSE - Archive Political Science and Policy Studies Supplement III | ||